Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BD Predicts Doubling Of Infusion Therapy In Wake Of Ohmeda Acquisition

This article was originally published in The Gray Sheet

Executive Summary

Becton Dickinson expects to more than double its infusion therapy (IT) business to $500 mil. in 1999, the first full fiscal year following the company's acquisition of Ohmeda's medical device division, IT worldwide division president Bob Adrion told analysts April 28 in New York City. For 1997, BD reported IT product sales of $228 mil.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT009977

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel